Dr. Alan Fletcher Joins PerkinElmer as Vice President of Bio-Discovery Business Development
PerkinElmer, Inc. announced that Alan Fletcher, Ph.D., has joined the Company as vice president, business development for PerkinElmer's Life and Analytical Sciences business. In this role, Fletcher will be responsible for growing the Bio-discovery business through the development of strategic partnerships and alliances in the life science research area, and the introduction of new technologies for GPCR, kinase and biomarker drug target classes.
Fletcher brings nearly 20 years of operational, technical and commercial experience in the drug discovery and life science industries to his new position. "Alan's arrival is an important next step in the growth of our Bio-discovery business," said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer. "He brings both strong expertise in technology and drug discovery, as well as proven leadership qualities that will be instrumental in further positioning PerkinElmer as the industry's leading provider of cellular screening and drug discovery reagent technologies and services."
Fletcher joins PerkinElmer from GE Healthcare where he held multiple positions in the company's life science and discovery systems business units. Prior to this, Fletcher held a range of leadership roles within consumer products, biotechnology, R&D, and technology transfer for a number of Fortune 500 corporations, where he gained extensive experience in business development, commercialization of biological and chemical research, strategy development, and technology assessment and development.
Fletcher has a doctorate in biochemical pharmacology from the University of London in the United Kingdom. He has been published widely in the areas of drug discovery and high throughput screening, and has served as a member of the board of directors for the Society of Biomolecular Sciences (SBS) since 2002 and as chairman of the board in 2005.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Amorfix and Ontario Genomics Institute announce partnership to accelerate development of blood test for Alzheimer's Disease
New Head of Marketing Communications and PR at JULABO
New test improves diagnosis of allergies - Higher diagnostic accuracy than standard tests
HeartBeat.bio raises € 4.5 million in Pre-Series A financing - New funds to drive development of organoid screening platform for cardiac drug discovery
New computer vision system designed to analyse cells in microscopy videos
Musical sensor shows bad medicine plays false note - Inspired by a musical instrument, the simple sensor can be constructed from common materials and used to detect adulterated or counterfeit drugs
PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12
How can we fight blood cancer more effectively? - Several hundred different treatment combinations to be tested simultaneously outside the body
LGC announces plans to expand forensic services with new facilities to be created in Runcorn, Cheshire
Synthetic Production of Potential Pharmaceuticals Dramatically Simplified by Scripps Research Team - Findings Could Expand Interest in Natural Products by Making Production More Cost-Effective
Light-induced shape shifting of MXenes - Femtosecond light creates switchable nano-waves in MXenes and moves the materials’ atoms at a record-breaking speed
